241 related articles for article (PubMed ID: 31228810)
21. Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
Hei YY; Zhang SQ; Feng Y; Wang J; Duan W; Zhang H; Mao S; Sun H; Xin M
Bioorg Med Chem; 2019 Oct; 27(20):114930. PubMed ID: 31176568
[TBL] [Abstract][Full Text] [Related]
22. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
[TBL] [Abstract][Full Text] [Related]
23. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα.
Yin Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
Eur J Med Chem; 2019 Nov; 182():111630. PubMed ID: 31446244
[TBL] [Abstract][Full Text] [Related]
24. (
Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
[TBL] [Abstract][Full Text] [Related]
25. Recent developments of small molecule PI3K/mTOR dual inhibitors.
Liu YN; Wan RZ; Liu ZP
Mini Rev Med Chem; 2013 Dec; 13(14):2047-59. PubMed ID: 24195664
[TBL] [Abstract][Full Text] [Related]
26. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
27. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
29. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
30. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Beaufils F; Cmiljanovic N; Cmiljanovic V; Bohnacker T; Melone A; Marone R; Jackson E; Zhang X; Sele A; Borsari C; Mestan J; Hebeisen P; Hillmann P; Giese B; Zvelebil M; Fabbro D; Williams RL; Rageot D; Wymann MP
J Med Chem; 2017 Sep; 60(17):7524-7538. PubMed ID: 28829592
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
Han F; Lin S; Liu P; Tao J; Yi C; Xu H
Bioorg Med Chem Lett; 2014 Sep; 24(18):4538-4541. PubMed ID: 25139570
[TBL] [Abstract][Full Text] [Related]
32. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
Barlaam B; Cosulich S; Degorce S; Fitzek M; Giordanetto F; Green S; Inghardt T; Hennequin L; Hancox U; Lambert-van der Brempt C; Morgentin R; Pass S; Plé P; Saleh T; Ward L
Bioorg Med Chem Lett; 2014 Aug; 24(16):3928-35. PubMed ID: 24992874
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).
Takeuchi CS; Kim BG; Blazey CM; Ma S; Johnson HW; Anand NK; Arcalas A; Baik TG; Buhr CA; Cannoy J; Epshteyn S; Joshi A; Lara K; Lee MS; Wang L; Leahy JW; Nuss JM; Aay N; Aoyama R; Foster P; Lee J; Lehoux I; Munagala N; Plonowski A; Rajan S; Woolfrey J; Yamaguchi K; Lamb P; Miller N
J Med Chem; 2013 Mar; 56(6):2218-34. PubMed ID: 23394126
[TBL] [Abstract][Full Text] [Related]
35. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.
Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ
Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Zhang J; Lv X; Ma X; Hu Y
Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
